Moderna Inc. [NASDAQ: MRNA] slipped around -4.52 points on Friday, while shares priced at $161.45 at the close of the session, down -2.72%. The company report on May 22, 2021 that Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine.
The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service.
Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.
Moderna Inc. stock is now 54.54% up from its year-to-date (YTD) trading value. MRNA Stock saw the intraday high of $169.28 and lowest of $161.35 per share. The company’s 52-week high price is 189.26, which means current price is +56.35% above from all time high which was touched on 02/08/21.
Compared to the average trading volume of 9.90M shares, MRNA reached a trading volume of 5153115 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc. [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $179.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on February 01, 2021. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $90 to $150, while Jefferies kept a Hold rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 10.18, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 24.39. The Price to Book ratio for the last quarter was 16.82, with the Price to Cash per share for the same quarter was set at 18.74. Price to Free Cash Flow for MRNA in the course of the last twelve months was 13.31 with Quick ratio for the last quarter at 1.30.
How has MRNA stock performed recently?
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.04. With this latest performance, MRNA shares dropped by -3.96% in over the last four-week period, additionally plugging by 81.63% over the last 6 months – not to mention a rise of 140.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 50.67, with the RSI for the last a single of trading hit 49.74, and the three-weeks RSI is set at 51.48 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 153.24, while it was recorded at 161.07 for the last single week of trading, and 118.31 for the last 200 days.
Moderna Inc. [MRNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +95.12. Moderna Inc.’s Net Margin is presently recorded at -92.99.
Return on Total Capital for MRNA is now -37.14, given the latest momentum, and Return on Invested Capital for the company is -36.66. Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 9.28. Additionally, MRNA Total Debt to Total Capital is recorded at 8.49, with Total Debt to Total Assets ending up at 3.24. Long-Term Debt to Equity for the company is recorded at 8.09, with the Long-Term Debt to Total Capital now at 7.41.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$574,665 per employee. Receivables Turnover for the company is 1.13 with a Total Asset Turnover recorded at a value of 0.18.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
Earnings analysis for Moderna Inc. [MRNA]
With the latest financial reports released by the company, Moderna Inc. posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Insider trade positions for Moderna Inc. [MRNA]
There are presently around $33,875 million, or 53.40% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,337,764, which is approximately 86.481% of the company’s market cap and around 2.50% of the total institutional ownership; BLACKROCK INC., holding 20,803,397 shares of the stock with an approximate value of $3.36 billion in MRNA stocks shares; and FLAGSHIP PIONEERING INC., currently with $3.32 billion in MRNA stock with ownership of nearly -33.333% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 463 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 43,413,330 shares. Additionally, 315 investors decreased positions by around 31,226,183 shares, while 88 investors held positions by with 135,179,732 shares. The mentioned changes placed institutional holdings at 209,819,245 shares, according to the latest SEC report filing. MRNA stock had 176 new institutional investments in for a total of 5,896,871 shares, while 96 institutional investors sold positions of 1,604,035 shares during the same period.